A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years

Inclusion Criteria: * Males and females aged between 8 and 18 years suffering from cerebral palsy or traumatic central nervous system injury. * Participant and/or authorised representative willing and able to give informed consent for participation in the study. * To have been under treatment for their spasticity for at least one year and to have reached a stage of non-progressive spasticity. * Participant able (in the investigators opinion) and willing to comply with all study requirements. * Participant has received inadequate efficacy and/or experienced unacceptable side effects from previous or current treatment with at least one of the following medications for spasticity: Baclofen, Diazepam (or another benzodiazepine), Dantrolene, Tizanidine, Gabapentin, Trihexyphenidyl. * Gross Motor Function Classification Scale Level III - V. * MAS of two or higher in at least one muscle group. * Participant and/or authorised representative willing for his or her name to be notified to the responsible authorities for participation in this study, as applicable in individual countries. * Participant and/or authorised representative willing to allow his or her primary care practitioner and consultant, if appropriate, to be notified of participation in the study. Exclusion Criteria: * Any known or suspected history of: * Schizophrenia or other psychotic illness, or diagnosis of schizophrenia in a first-degree relative. * Alcohol or substance abuse. * Any known or suspected hype…